[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Osimertinib\" }]"}]},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"hepatic"},{"field":"source"}]},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"cancers"},{"field":"setting"},{"field":"intent"},{"field":"cycleDays"},{"field":"cycles"},{"field":"components"},{"field":"emetogenicity"},{"field":"gcsf"},{"field":"trials"},{"field":"source"},{"field":"notes"},{"field":"asOf"}]},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.\"","after":"\"Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.\""}]}]